

Supporting Information

Bond Energy Enabled Amines Distinguishing: Chemo-, Regioselective 1,3-Diamination of (Trifluoromethyl)alkenes with Different Amines by Two C(sp³)-F Bonds Cleavage

Hao Zeng[#], Hengyuan Li[#], Chengxi Li, Huanfeng Jiang, Chuanle Zhu*

School of Chemistry and Chemical Engineering, Key Laboratory of Functional Molecular
Engineering of Guangdong Province, South China University of Technology, Guangzhou 510640,
P. R. China

E-mail: cechlzhu@scut.edu.cn; Fax and Tel.: (+86) 20-87112906

A. General information	2
B. Optimization of the Reaction Conditions.....	3
C. General Procedure for 1,3-Diamination of (Trifluoromethyl)alkenes 2.....	4
1) The Distinguishing between Indole Derivatives 1 and Sulfonamide 3.	4
2) The Distinguishing between Arylsulfonamides and Alkylsulfonamide.....	4
3) Gram-Scale Reaction of Indole 1a, (Trifluoromethyl)alkene 2a, and Sulfonamide 3a..	5
D. Analysis Data for the Products	5
E. Late-stage Functionalization of Drug Molecules.....	17
F. X-ray Crystallographic Data.....	20
G. NMR Spectra of New Compounds	23

A. General information


Melting points were measured using a melting point instrument and are uncorrected. Chemical shifts were reported in ppm from the solvent resonance as the internal standard (CDCl_3 $\delta_{\text{H}} = 7.26$ ppm, $\delta_{\text{C}} = 77.16$ ppm). Multiplicity was indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet). Coupling constants were reported in Hertz (Hz). IR spectra were obtained with an infrared spectrometer on either potassium bromide pellets or liquid films between two potassium bromide pellets. HRMS was carried out on a high-resolution mass spectrometer (Agilent 6210 ESI/TOF MS or Thermo Q Exactive Plus). TLC was performed using commercially available 100–400 mesh silica gel plates (GF₂₅₄). X-ray structural analyses were conducted on Bruker APEX-II CCD Diffractometer.

Materials. Tetrahydrofuran (THF) and toluene were distilled from sodium/benzophenone; 1,2-dichloroethane (DCE) was distilled from calcium hydride; acetonitrile (CH_3CN) was distilled from phosphorus pentoxide. Other commercially available reagents were purchased and used without further purification. Analytical thin-layer chromatography was performed on 0.20 mm silica gel plates (GF₂₅₄) using UV light as a visualizing agent. Flash column chromatography was carried out using silica gel (200–300 mesh) with the indicated solvent system. All reactions were conducted in oven-dried Schlenk tubes. All the reaction temperatures reported are oil bath or ethanol bath temperatures. All the indole derivatives (**1a–1l**) were purchased and used directly. The (trifluoromethyl)alkenes **2** were synthesized according to the reported methods.¹ All the used sulfonylamides (**1m**, **1n**, **3a**, **3b**, **3c**, **8a** and **8b**) were known compounds, among which **3a** and **3c** were purchased and used directly, while **1m**^{2a}, **1n**^{2a}, **3b**^{2a}, **8a**^{2b} and **8b**^{2b} were synthesized according reported methods.

References

- (1) Xia, P.-J.; Ye, Z.-P.; Hu, Y.-Z.; Song, D.; Xiang, H.-Y.; Chen, X.-Q.; Yang, H. *Org. Lett.* **2019**, *21*, 2658–2662.
- (2) (a) Wang H.-P.; Sun, S.; Cheng, J. *Org. Lett.* **2017**, *19*, 5844–5847. (b) Feng, J.; Liu, S.; Tian, X.; Fan, S.; Huang, J.; Li, L. CN 107540726[A]. 2018.

B. Optimization of the Reaction Conditions.




entry	base	solvent	NMR yield of 4a/5a/6a/7a	yield of 4a (%) ^b
1	Cs ₂ CO ₃	DMF	30/0/21/22	30 (Z/E = 7:1)
2	Cs ₂ CO ₃	1,4-dioxane	0/0/0/0	0
3	Cs ₂ CO ₃	MeCN	0/0/0/0	0
4	Cs ₂ CO ₃	DCE	0/0/0/0	0
5	Cs ₂ CO ₃	toluene	0/0/0/0	0
6	Cs ₂ CO ₃	EtOH	0/0/0/0	0
7	K ₂ CO ₃	DMF	16/0/0/34	15 (Z/E = 7:1)
8	Li ₂ CO ₃	DMF	0/0/0/0	0
9	t-BuOK	DMF	5/0/50/27	-
10	t-BuONa	DMF	2/0/39/27	-
11	t-BuOLi	DMF	75/0/16/10	75 (Z/E = 7:1)
12	Et ₃ N	DMF	0/0/0/0	0
13	DBU	DMF	0/0/0/0	0
14	DABCO	DMF	0/0/0/0	0
15	-	DMF	0/0/0/0	0
16 ^c	t-BuOLi	DMF	60/0/23/19	60 (Z/E = 4:1)
17 ^d	t-BuOLi	DMF	35/0/37/28	35 (Z/E = 8:1)

Product **5a** and all the *ipso*, *ipso*-diamination products were not obtained under all these conditions.


C. General Procedure for 1,3-Diamination of (Trifluoromethyl)alkenes 2.

1) The Distinguishing between Indole Derivatives 1 and Sulfonamide 3.




A 25 mL oven-dried Schlenk tube charged with a magnetic stirring bar, (trifluoromethyl)alkenes **2** (0.4 mmol) was added to the suspension of *t*-BuOLi (0.6 mmol), indole derivatives **1** (0.22 mmol), sulfonamides **3** (0.2 mmol) and DMF (4 mL) at -5 °C. The reaction mixture was vigorously stirred at -5 °C for 24 h. Then the mixture was stopped stirring, added water (15 mL), extracted with EtOAc (15 mL × 3). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. Further purification by flash column chromatography on silica gel (eluting with petroleum ether/ethyl acetate) provided the product **4**.

2) The Distinguishing between Arylsulfonamides and Alkylsulfonamide.



t-BuOLi (5 equiv) was added to the solution of *N*-methylsulfonamide **1m** or **1n** (0.2 mmol), (trifluoromethyl)alkene **2a** (4 equiv) in DMF (4 mL). Then *N*-methylmethanesulfonamide **3c** (5 equiv) was added by portions to the mixture within 20 minutes. The reaction mixture was vigorously stirred at room temperature for 6 h. Then the mixture was stopped stirring, added water (15 mL), extracted with EtOAc (15 mL × 3). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. Further purification by flash column chromatography on silica gel (eluting with petroleum ether/ethyl acetate) provided the product **4m/4n**.


3) Gram-Scale Reaction of Indole **1a, (Trifluoromethyl)alkene **2a**, and Sulfonamide **3a**.**



A 250 mL oven-dried Schlenk tube charged with a magnetic stirring bar, (trifluoromethyl)alkene **2a** (1376 mg, 8 mmol) was added to the suspension of *t*-BuOLi (960 mg, 12 mmol), indole **1a** (514.8 mg, 4.4 mmol), sulfonamide **3a** (740 mg, 4 mmol) and DMF (80 mL) at -5 °C. The reaction mixture was vigorously stirred at -5 °C for 24 h. Then the mixture was stopped stirring, added water (150 mL), extracted with EtOAc (150 mL × 3). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. Further purification by flash column chromatography on silica gel (eluting with petroleum ether/ethyl acetate = 10:1) provided the product **4a** (1.233 g, 71% yield, Z/E = 7/1).


D. Analysis Data for the Products

(Z)-N-(3-Fluoro-3-(1*H*-Indol-1-yl)-2-Phenylallyl)-N,4-Dimethylbenzenesulfonamide (4a)



65.2 mg, 75% yield, Z/E = 7:1; eluent with petroleum ether/ethyl acetate = 10:1; white solid, mp: 138–139 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.67 (d, *J* = 8.0 Hz, 2H), 7.58 (d, *J* = 7.2 Hz, 1H), 7.36–7.39 (m, 1H), 7.34 (d, *J* = 8.4 Hz, 2H), 7.17–7.27 (m, 5H), 7.07–7.09 (m, 2H), 6.77 (d, *J* = 3.6 Hz, 1H), 6.47 (d, *J* = 3.2 Hz, 1H), 4.39 (d, *J* = 2.8 Hz, 2H), 2.80 (s, 3H), 2.47 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 147.8 (d, ¹*J*_{F-C} = 264.0 Hz), 143.6, 135.6 (d, ³*J*_{F-C} = 3.7 Hz), 134.2, 133.4 (d, ³*J*_{F-C} = 3.2 Hz), 129.8, 128.8, 128.6, 128.2 (d, ³*J*_{F-C} = 3.1 Hz), 128.0, 127.7, 127.3 (d, ⁴*J*_{F-C} = 2.1 Hz), 123.4, 121.7, 121.2, 111.4 (d, ³*J*_{F-C} = 3.0 Hz), 109.3 (d, ²*J*_{F-C} = 24.0 Hz), 105.9 (d, ⁴*J*_{F-C} = 1.2 Hz), 48.3 (d, ³*J*_{F-C} = 2.6 Hz), 34.2, 21.6; ¹⁹F NMR (376 MHz, CDCl₃) δ -88.7 (s, 1F); IR (KBr): 3056, 2927, 1692, 1456, 1341, 744 cm⁻¹; HRMS (ESI, m/z): [M+H]⁺ Calcd. For C₂₅H₂₃FN₂O₂S+H, 435.1543; found, 435.1547.

(Z)-N-(3-Fluoro-3-(4-Methyl-1*H*-Indol-1-yl)-2-Phenylallyl)-*N*,4-Dimethylbenzenesulfonamide (4b)




65.5 mg, 73% yield, *Z/E* = 13:1; eluent with petroleum ether/ethyl acetate = 10:1; colorless oil; ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.69 (d, *J* = 8.0 Hz, 2H), 7.46 (d, *J* = 8.0 Hz, 2H), 7.21 (d, *J* = 3.2 Hz, 1H), 7.11–7.19 (m, 6H), 7.07 (t, *J* = 8.0 Hz, 1H), 6.91 (d, *J* = 7.2 Hz, 1H), 6.59 (d, *J* = 2.8 Hz, 1H), 4.27 (s, 2H), 2.67 (s, 3H), 2.41 (s, 6H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 146.9 (d, ¹*J*_{*F-C*} = 266.7 Hz), 144.1, 135.6 (d, ³*J*_{*F-C*} = 3.6 Hz), 133.8 (d, ³*J*_{*F-C*} = 3.3 Hz), 133.7, 130.4, 128.7, 128.5 (d, ³*J*_{*F-C*} = 2.9 Hz), 128.4, 128.2, 128.1, 128.0, 127.9, 123.6, 122.1, 112.1 (d, ²*J*_{*F-C*} = 25.4 Hz), 108.8, 104.5, 49.0, 35.0, 21.5, 18.6; ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -86.9 (s, 1F); IR (KBr): 3049, 2926, 1692, 1443, 1340, 749 cm⁻¹; HRMS (ESI, m/z): [M+H]⁺ Calcd. For C₂₆H₂₅FN₂O₂S+H, 449.1699; found, 449.1698.

(Z)-N-(3-Fluoro-3-(5-Methyl-1*H*-Indol-1-yl)-2-Phenylallyl)-*N*,4-Dimethylbenzenesulfonamide (4c)



53.8 mg, 60% yield, *Z/E* = 16:1; eluent with petroleum ether/ethyl acetate = 10:1; colorless oil; ¹H NMR (500 MHz, CDCl₃) δ 7.61 (d, *J* = 8.0 Hz, 2H), 7.27–7.31 (m, 3H), 7.21 (d, *J* = 8.0 Hz, 1H), 7.13 (d, *J* = 4.5 Hz, 3H), 7.02–7.03 (m, 3H), 6.66 (d, *J* = 3.5 Hz, 1H), 6.33 (d, *J* = 3.0 Hz, 1H), 4.32 (s, 2H), 2.73 (s, 3H), 2.42 (s, 3H), 2.40 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 148.0 (d, ¹*J*_{*F-C*} = 263.4 Hz), 143.6, 134.1, 133.9 (d, ³*J*_{*F-C*} = 3.6 Hz), 133.4 (d, ³*J*_{*F-C*} = 2.9 Hz), 131.2, 129.8, 129.1, 128.6, 128.2 (d, ³*J*_{*F-C*} = 2.9 Hz), 127.9, 127.7, 127.4 (d, ⁴*J*_{*F-C*} = 1.8 Hz), 124.9, 120.9, 111.1 (d, ³*J*_{*F-C*} = 3.0 Hz), 108.7 (d, ²*J*_{*F-C*} = 24.2 Hz), 105.6, 48.3 (d, ³*J*_{*F-C*} = 2.6 Hz), 34.1, 21.6, 21.4; ¹⁹F NMR (471 MHz, CDCl₃) δ -88.7 (s, 1F); IR (KBr): 3037, 2925, 1691, 1466, 1340, 744 cm⁻¹; HRMS (ESI, m/z): [M+H]⁺ Calcd. For C₂₆H₂₅FN₂O₂S+H, 449.1699; found, 449.1696.


(Z)-N-(3-Fluoro-3-(4-Methoxy-1*H*-Indol-1-yl)-2-Phenylallyl)-*N*,4-Dimethylbenzenesulfonamide (4d)



55.8 mg, 60% yield, *Z/E* > 30:1; eluent with petroleum ether/ethyl acetate = 10:1; yellow oil; ¹H NMR (400 MHz, CDCl₃) δ 7.64 (d, *J* = 7.6 Hz, 2H), 7.33 (d, *J* = 8.0 Hz, 2H), 7.28 (s, 1H), 7.16 (d, *J* = 5.2 Hz, 3H), 7.05–7.06 (m, 2H), 6.97 (d, *J* = 8.0 Hz, 1H), 6.66 (d, *J* = 3.6 Hz, 1H), 6.60 (d, *J* = 7.6 Hz, 1H), 6.57 (d, *J* = 2.8 Hz, 1H), 4.35 (s, 2H), 3.94 (s, 3H), 2.77 (s, 3H), 2.46 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 153.3, 147.9 (d, ¹*J*_{F-C} = 265.8 Hz), 143.7, 137.0 (d, ³*J*_{F-C} = 3.6 Hz), 134.1, 133.3 (d, ³*J*_{F-C} = 3.2 Hz), 129.8, 128.7, 128.2 (d, ³*J*_{F-C} = 3.0 Hz), 128.0, 127.7, 125.9 (d, ⁴*J*_{F-C} = 2.1 Hz), 124.4, 119.3, 109.5 (d, ²*J*_{F-C} = 24.0 Hz), 104.6, 103.1, 101.8, 55.5, 48.36, 34.2, 21.7; ¹⁹F NMR (376 MHz, CDCl₃) δ -88.6 (s, 1F); IR (KBr): 3055, 2929, 1691, 1454, 1338, 741 cm⁻¹; HRMS (ESI, m/z): [M+H]⁺ Calcd. For C₂₆H₂₅FN₂O₃S+H, 465.1648; found, 465.1651.

(*Z*)-*N*-(3-Fluoro-3-(5-Methoxy-1*H*-Indol-1-yl)-2-Phenylallyl)-*N*,4-


Dimethylbenzenesulfonamide (4e)



61.3 mg, 66% yield, *Z/E* > 30:1; eluent with petroleum ether/ethyl acetate = 10:1; colorless oil; ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.69 (d, *J* = 7.6 Hz, 2H), 7.46 (d, *J* = 8.0 Hz, 2H), 7.38 (d, *J* = 8.4 Hz, 1H), 7.21 (d, *J* = 3.2 Hz, 1H), 7.15 (s, 5H), 6.75 (s, 1H), 6.71 (d, *J* = 8.8 Hz, 1H), 6.50 (d, *J* = 2.8 Hz, 1H), 4.28 (s, 2H), 3.69 (s, 3H), 2.66 (s, 3H), 2.42 (s, 3H); ¹³C NMR (101 MHz, DMSO-*d*₆) δ 157.0, 146.7 (d, ¹*J*_{F-C} = 266.4 Hz), 144.1, 136.4 (d, ³*J*_{F-C} = 3.4 Hz), 133.9 (d, ³*J*_{F-C} = 3.4 Hz), 133.6, 130.4, 128.7, 128.5 (d, ³*J*_{F-C} = 2.8 Hz), 128.2, 127.9, 127.0 (d, ³*J*_{F-C} = 3.0 Hz), 122.3, 121.8, 111.6 (d, ²*J*_{F-C} = 25.6 Hz), 111.5, 106.0, 95.0, 55.7, 49.0, 35.0, 21.5; ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -86.8 (s, 1F); IR (KBr): 3057, 2933, 1691, 1452, 1341, 742 cm⁻¹; HRMS (ESI, m/z): [M+H]⁺ Calcd. For C₂₆H₂₅FN₂O₃S+H, 465.1648; found, 465.1650.


(*Z*)-*N*-(3-Fluoro-3-(4-Fluoro-1*H*-Indol-1-yl)-2-Phenylallyl)-*N*,4-

Dimethylbenzenesulfonamide(4f)




52.5 mg, 58% yield, $Z/E > 30:1$; eluent with petroleum ether/ethyl acetate = 10:1; light yellow oil; ^1H NMR (400 MHz, DMSO- d_6) δ 7.69 (d, $J = 8.0$ Hz, 2H), 7.46 (d, $J = 7.6$ Hz, 2H), 7.37 (d, $J = 3.2$ Hz, 1H), 7.11–7.21 (m, 7H), 6.88–6.93 (m, 1H), 6.64 (d, $J = 3.2$ Hz, 1H), 4.28 (s, 2H), 2.67 (s, 3H), 2.42 (s, 3H); ^{13}C NMR (101 MHz, DMSO- d_6) δ 155.6 (d, $^{1}J_{F-C} = 245.7$ Hz), 146.1 (d, $^{1}J_{F-C} = 266.9$ Hz), 144.1, 138.3 (d, $^{3}J_{F-C} = 3.6$ Hz), 138.1 (d, $^{3}J_{F-C} = 3.6$ Hz), 133.7, 133.5 (d, $^{3}J_{F-C} = 3.2$ Hz), 130.4, 129.3 (d, $^{4}J_{F-C} = 2.8$ Hz), 128.7, 128.4–128.5 (m), 127.8, 124.5 (d, $^{3}J_{F-C} = 7.6$ Hz), 117.2 (d, $^{2}J_{F-C} = 22.9$ Hz), 113.3 (d, $^{2}J_{F-C} = 24.6$ Hz), 107.9, 106.9 (d, $J = 18.7$ Hz), 101.3, 49.0, 35.1, 21.5; ^{19}F NMR (376 MHz, DMSO- d_6) δ -87.7 (s, 1F), -121.9 – -121.9 (m, 1F); IR (KBr): 3054, 2928, 1695, 1453, 1338, 746 cm^{-1} ; HRMS (ESI, m/z): [M+H] $^{+}$ Calcd. For $\text{C}_{25}\text{H}_{22}\text{F}_2\text{N}_2\text{O}_2\text{S}+\text{H}$, 453.1448; found, 453.1439.

(Z)-N-(3-(4-Chloro-1*H*-Indol-1-yl)-3-Fluoro-2-Phenylallyl)-N,4-Dimethylbenzenesulfonamide(4g)



52.5 mg, 56% yield, $Z/E > 30:1$; eluent with petroleum ether/ethyl acetate = 10:1; colorless oil; ^1H NMR (400 MHz, DMSO- d_6) δ 7.68 (d, $J = 7.6$ Hz, 2H), 7.46 (d, $J = 6.0$ Hz, 3H), 7.34 (d, $J = 6.4$ Hz, 1H), 7.13–7.17 (m, 7H), 6.60 (s, 1H), 4.28 (s, 2H), 2.67 (s, 3H), 2.42 (s, 3H); ^{13}C NMR (101 MHz, DMSO- d_6) δ 146.0 (d, $^{1}J_{F-C} = 265.1$ Hz), 144.1, 136.5 (d, $^{3}J_{F-C} = 3.5$ Hz), 133.7, 133.4 (d, $^{3}J_{F-C} = 3.2$ Hz), 130.4, 130.0 (d, $^{3}J_{F-C} = 3.0$ Hz), 128.7, 128.5, 128.4, 127.8, 126.9, 125.3, 124.6, 121.5, 113.5 (d, $^{2}J_{F-C} = 24.4$ Hz), 110.5, 103.7, 49.0, 35.1, 21.5; ^{19}F NMR (376 MHz, DMSO- d_6) δ -87.6 (s, 1F); IR (KBr): 3037, 2926, 1690, 1439, 1338, 751 cm^{-1} ; HRMS (ESI, m/z): [M+H] $^{+}$ Calcd. For $\text{C}_{25}\text{H}_{22}\text{FClN}_2\text{O}_2\text{S}+\text{H}$, 469.1153; found, 469.1150.


(Z)-N-(3-(5-Chloro-1*H*-Indol-1-yl)-3-Fluoro-2-Phenylallyl)-N,4-Dimethylbenzenesulfonamide(4h)



54.4 mg, 58% yield, $Z/E = 21:1$; eluent with petroleum ether/ethyl acetate = 10:1; colorless oil; ^1H NMR (400 MHz, DMSO- d_6) δ 7.68 (d, $J = 7.6$ Hz, 2H), 7.59 (s, 1H), 7.45 (d, $J = 8.0$ Hz, 2H),


7.38 (d, $J = 2.4$ Hz, 1H), 7.34 (d, $J = 8.8$ Hz, 1H), 7.10–7.17 (m, 6H), 6.56 (d, $J = 2.4$ Hz, 1H), 4.27 (s, 2H), 2.67 (s, 3H), 2.41 (s, 3H); ^{13}C NMR (101 MHz, DMSO- d_6) δ 146.1 (d, $^1J_{F-C} = 266.8$ Hz), 144.1, 134.2 (d, $^3J_{F-C} = 3.6$ Hz), 133.7, 133.5 (d, $^3J_{F-C} = 3.2$ Hz), 130.4, 129.8, 128.7, 128.4 (d, $^3J_{F-C} = 2.9$ Hz), 128.4, 128.0, 127.8, 126.4, 123.4, 120.7, 112.9 (d, $^2J_{F-C} = 24.6$ Hz), 112.8, 105.6, 49.0, 35.1, 21.5; ^{19}F NMR (376 MHz, DMSO- d_6) δ -87.4 (s, 1F); IR (KBr): 3057, 2925, 1692, 1453, 1339, 744 cm^{-1} ; HRMS (ESI, m/z): [M+H] $^+$ Calcd. For $\text{C}_{25}\text{H}_{22}\text{FClN}_2\text{O}_2\text{S}+\text{H}$, 469.1153; found, 469.1151.

(Z)-N-(3-(5-Bromo-1*H*-Indol-1-yl)-3-Fluoro-2-Phenylallyl)-N,4-Dimethylbenzenesulfonamide(4i)



77.0 mg, 75% yield, $Z/E = 18:1$; eluent with petroleum ether/ethyl acetate = 10:1; yellow oil; ^1H NMR (500 MHz, DMSO- d_6) δ 7.68 (d, $J = 7.5$ Hz, 2H), 7.54 (s, 1H), 7.45–7.47 (m, 3H), 7.36 (s, 1H), 7.21 (d, $J = 8.0$ Hz, 1H), 7.11–7.17 (m, 5H), 6.59 (s, 1H), 4.27 (s, 2H), 2.65 (s, 3H), 2.42 (s, 3H); ^{13}C NMR (126 MHz, DMSO) δ 145.9 (d, $^1J_{F-C} = 266.7$ Hz), 144.1, 136.3 (d, $^3J_{F-C} = 3.0$ Hz), 133.7, 133.6 (d, $^3J_{F-C} = 3.2$ Hz), 130.4, 129.7 (d, $^3J_{F-C} = 2.8$ Hz), 128.7, 128.5 (d, $^4J_{F-C} = 2.5$ Hz), 128.4, 127.8, 127.6, 124.8, 123.0, 116.3, 114.2, 113.0 (d, $^2J_{F-C} = 24.7$ Hz), 106.1, 49.0, 35.2, 21.5; ^{19}F NMR (471 MHz, DMSO- d_6) δ -87.8 (s, 1F); IR (KBr): 3059, 2932, 1700, 1462, 1188, 938 cm^{-1} ; HRMS (ESI, m/z): [M+H] $^+$ Calcd. For $\text{C}_{25}\text{H}_{22}\text{BrFN}_2\text{O}_2\text{S}+\text{H}$, 513.0648; found, 513.0652.


(Z)-N-(3-(5-Cyano-1*H*-Indol-1-yl)-3-Fluoro-2-Phenylallyl)-N,4-Dimethylbenzenesulfonamide (4j)



62.5 mg, 68% yield, $Z/E = 8:1$; eluent with petroleum ether/ethyl acetate = 6:1; colorless oil; ^1H NMR (400 MHz, CDCl_3) δ 7.32–7.88 (m, 8H), 6.53–7.19 (m, 6H), 4.35 (d, $J = 2.8$ Hz, 2H), 2.75 (s, 3H), 2.46 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 146.3 (d, $^1J_{F-C} = 266.0$ Hz), 143.8, 137.3 (d, $^3J_{F-C} = 3.4$ Hz), 134.1, 132.7 (d, $^3J_{F-C} = 3.3$ Hz), 129.9, 128.9, 128.6, 128.5, 128.1, 127.7, 126.5 (d, $^4J_{F-C} = 2.5$ Hz), 120.0, 112.3 (d, $^4J_{F-C} = 2.0$ Hz), 111.7 (d, $J = 22.9$ Hz), 106.2, 105.2, 48.4 (d, $^3J_{F-C}$

= 2.9 Hz), 34.7, 21.6; ¹⁹F NMR (376 MHz, CDCl₃) δ -89.7 (s, 1F); IR (KBr): 3038, 2919, 1639, 1461, 1159, 745 cm⁻¹; HRMS (APCI, m/z): [M+H]⁺ Calcd. For C₂₆H₂₂FN₃O₂S+H, 460.1490; found, 460.1481.

(Z)-N-(3-Fluoro-3-(1*H*-Indol-1-yl)-2-Phenylallyl)-4-Methoxy-N-Methylbenzenesulfonamide (4k)




64.9 mg, 72% yield, Z/E = 23:1; eluent with petroleum ether/ethyl acetate = 6:1; white solid, mp: 177–178 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.70 (d, J = 8.8 Hz, 2H), 7.57 (d, J = 7.6 Hz, 1H), 7.36 (d, J = 8.1 Hz, 1H), 7.15–7.26 (m, 5H), 7.05–7.07 (m, 2H), 6.99 (d, J = 9.2 Hz, 2H), 6.76 (d, J = 3.2 Hz, 1H), 6.46 (d, J = 3.6 Hz, 1H), 4.36 (d, J = 2.8 Hz, 2H), 3.89 (s, 3H), 2.78 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 163.1, 147.8 (d, ¹J_{F-C} = 265.6 Hz), 135.6 (d, ³J_{F-C} = 3.9 Hz), 133.4 (d, ³J_{F-C} = 3.1 Hz), 129.8, 128.8, 128.7, 128.6, 128.2 (d, ³J_{F-C} = 3.2 Hz), 128.0, 127.3, 123.4, 121.7, 121.2, 114.4, 111.4 (d, ³J_{F-C} = 2.9 Hz), 109.4 (d, ²J_{F-C} = 24.0 Hz), 105.9, 55.7, 48.3, 34.2; ¹⁹F NMR (376 MHz, CDCl₃) δ -88.7 (s, 1F); IR (KBr): 3060, 2936, 1691, 1459, 1336, 744 cm⁻¹; HRMS (ESI, m/z): [M+H]⁺ Calcd. For C₂₅H₂₃FN₂O₃S+H, 451.1492; found, 451.1490.

(Z)-N-(3-Fluoro-3-(1*H*-Indol-1-yl)-2-Phenylallyl)-N-Methylmethanesulfonamide (4l)




31.5 mg, 44% yield, Z/E > 30:1; eluent with petroleum ether/ethyl acetate = 10:1; colorless oil; ¹H NMR (400 MHz, CDCl₃) δ 7.59 (d, J = 7.6 Hz, 1H), 7.4 (dd, J = 8.0, 2.0 Hz, 1H), 7.28–7.30 (m, 1H), 7.18–7.23 (m, 4H), 7.09 (d, J = 3.6 Hz, 1H), 7.07 (d, J = 2.4 Hz, 1H), 6.77 (d, J = 3.6 Hz, 1H), 6.47 (d, J = 3.2 Hz, 1H), 4.60 (d, J = 2.4 Hz, 2H), 2.97 (s, 3H), 2.47 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 147.9 (d, ¹J_{F-C} = 265.5 Hz), 135.7 (d, ³J_{F-C} = 3.8 Hz), 133.5 (d, ³J_{F-C} = 3.5 Hz), 128.8, 128.8, 128.3 (d, ³J_{F-C} = 3.2 Hz), 128.3, 127.3, 123.5, 121.8, 121.2, 111.4 (d, ³J_{F-C} = 3.2 Hz), 109.4 (d, ²J_{F-C} = 24.5 Hz), 106.0, 48.1, 36.6, 33.6; ¹⁹F NMR (376 MHz, CDCl₃) δ -89.2 (s, 1F); IR (KBr): 3045, 2930, 1692, 1451, 1320, 754 cm⁻¹; HRMS (ESI, m/z): [M+H]⁺ Calcd. For C₁₉H₁₉FN₂O₂S+H, 359.1224; found, 359.1217.

(Z)-4-Bromo-N-(1-Fluoro-3-(N-Methylmethysulfonamido)-2-Phenylprop-1-en-1-yl)-N-Methylbenzenesulfonamide (4m)




78.6 mg, 80% yield, Z/E = 8:1; eluent with petroleum ether/ethyl acetate = 10:1; colorless oil; ^1H NMR (400 MHz, CDCl_3) δ 7.60–7.63 (m, 2H), 7.56–7.58 (m, 2H), 7.36–7.44 (m, 5H), 4.33 (d, J = 2.8 Hz, 2H), 2.86 (s, 3H), 2.81 (d, J = 2.0 Hz, 3H), 2.40 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 149.1 (d, $^1J_{F-C}$ = 279.4 Hz), 137.1, 133.7 (d, $^3J_{F-C}$ = 3.0 Hz), 132.5, 129.5 (d, $^4J_{F-C}$ = 1.8 Hz), 128.9, 128.8, 128.7, 128.7, 116.5 (d, $^2J_{F-C}$ = 27.9 Hz), 48.6 (d, $^4J_{F-C}$ = 2.3 Hz), 37.0 (d, $^4J_{F-C}$ = 3.0 Hz), 36.2, 33.8; ^{19}F NMR (376 MHz, CDCl_3) δ -91.6 (s, 1F); IR (KBr): 3049, 2960, 1692, 1459, 1336, 742 cm^{-1} ; HRMS (ESI, m/z): [M+H] $^+$ Calcd. For $\text{C}_{18}\text{H}_{20}\text{BrFN}_2\text{O}_4\text{S}_2+\text{H}$, 491.0105; found, 491.0101.

(Z)-N-(1-Fluoro-3-(N-Methylmethysulfonamido)-2-Phenylprop-1-en-1-yl)-N-Methyl-4-Nitrobenzenesulfonamide (4n)




73.2 mg, 80% yield, Z/E > 30:1; eluent with petroleum ether/ethyl acetate = 6:1; white solid, mp: 136–137 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.29 (d, J = 8.8 Hz, 2H), 7.89 (d, J = 8.4 Hz, 2H), 7.36–7.42 (m, 5H), 4.33 (d, J = 2.4 Hz, 2H), 2.87 (d, J = 2.0 Hz, 3H), 2.85 (s, 3H), 2.43 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 150.5, 148.5 (d, $^1J_{F-C}$ = 277.0 Hz), 143.7, 133.4 (d, $^3J_{F-C}$ = 3.1 Hz), 129.2 (d, $^4J_{F-C}$ = 1.8 Hz), 129.0, 128.8, 128.6 (d, $^3J_{F-C}$ = 3.2 Hz), 124.4, 117.1 (d, $^2J_{F-C}$ = 27.2 Hz), 48.6 (d, $^4J_{F-C}$ = 2.1 Hz), 36.9 (d, $^3J_{F-C}$ = 3.9 Hz), 36.5, 33.9 (d, $^3J_{F-C}$ = 3.6 Hz); ^{19}F NMR (471 MHz, CDCl_3) δ -91.8 (s, 1F); IR (KBr): 3090, 2934, 1695, 1459, 1341, 771 cm^{-1} ; HRMS (ESI, m/z): [M+H] $^+$ Calcd. For $\text{C}_{18}\text{H}_{20}\text{FN}_3\text{O}_6\text{S}_2+\text{H}$, 458.0850; found, 458.0846.

(Z)-N-(3-Fluoro-3-(1*H*-Indol-1-yl)-2-(*p*-Tolyl)allyl)-*N*,4-Dimethylbenzenesulfonamide (4o)



62.8 mg, 70% yield, *Z/E* = 17:1; eluent with petroleum ether/ethyl acetate = 10:1; red oil; ¹H NMR (400 MHz, CDCl₃) δ 7.62 (d, *J* = 8.4 Hz, 2H), 7.53 (d, *J* = 7.6 Hz, 1H), 7.33 (d, *J* = 8.0 Hz, 1H), 7.28 (d, *J* = 8.0 Hz, 2H), 7.14–7.23 (m, 2H), 6.89–6.94 (m, 4H), 6.72 (d, *J* = 3.2 Hz, 1H), 6.42 (d, *J* = 3.6 Hz, 1H), 4.31 (d, *J* = 2.4 Hz, 2H), 2.73 (s, 3H), 2.42 (s, 3H), 2.21 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 147.5 (d, ¹J_{F-C} = 263.4 Hz), 143.6, 137.8, 135.7 (d, ³J_{F-C} = 3.8 Hz), 134.2, 130.2 (d, ³J_{F-C} = 3.2 Hz), 129.8, 129.4, 128.8, 128.0 (d, ³J_{F-C} = 3.1 Hz), 127.7, 127.4 (d, ⁴J_{F-C} = 2.2 Hz), 123.4, 121.7, 121.1, 111.4 (d, ³J_{F-C} = 3.0 Hz), 109.3 (d, ²J_{F-C} = 23.8 Hz), 105.8, 48.6 (d, ³J_{F-C} = 2.8 Hz), 34.2, 21.6, 21.2; ¹⁹F NMR (376 MHz, CDCl₃) δ -91.0 (s, 1F); IR (KBr): 3048, 2925, 1693, 1456, 1341, 745 cm⁻¹; HRMS (ESI, m/z): [M+H]⁺ Calcd. For C₂₆H₂₅FN₂O₂S+H, 449.1699; found, 449.1692.


(Z)-N-(2-(3,4-Dimethylphenyl)-3-Fluoro-3-(1*H*-Indol-1-yl)allyl)-*N*,4-Dimethylbenzenesulfonamide (4p)



62.9 mg, 68% yield, *Z/E* = 9:1; eluent with petroleum ether/ethyl acetate = 10:1; light yellow oil; ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, *J* = 8.0 Hz, 2H), 7.58 (d, *J* = 7.6 Hz, 1H), 7.39 (d, *J* = 8.4 Hz, 1H), 7.33 (d, *J* = 7.6 Hz, 2H), 7.19–7.29 (m, 2H), 6.90 (d, *J* = 8.0 Hz, 1H), 6.82 (s, 1H), 6.72–6.77 (m, 2H), 6.46 (d, *J* = 3.2 Hz, 1H), 4.35 (s, 2H), 2.79 (s, 3H), 2.47 (s, 3H), 2.17 (s, 3H), 2.09 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 147.5 (d, ¹J_{F-C} = 262.9 Hz), 143.5, 136.7, 136.4, 135.8 (d, ³J_{F-C} = 3.7 Hz), 134.3, 130.5 (d, ³J_{F-C} = 3.0 Hz), 129.8, 129.8, 129.2 (d, ³J_{F-C} = 3.2 Hz), 128.8, 127.7, 127.5, 125.5 (d, ³J_{F-C} = 2.9 Hz), 123.4, 121.6, 121.1, 111.5 (d, ³J_{F-C} = 3.1 Hz), 109.3 (d, ²J_{F-C} = 23.4 Hz), 105.7 (d, ⁴J_{F-C} = 1.1 Hz), 48.3 (d, ³J_{F-C} = 2.8 Hz), 34.1, 21.7, 19.8, 19.6; ¹⁹F NMR (376 MHz, CDCl₃) δ -87.2 (s, 1F); IR (KBr): 3047, 2926, 1689, 1456, 1341, 750 cm⁻¹; HRMS (ESI, m/z): [M+H]⁺ Calcd. For C₂₇H₂₇FN₂O₂S+H, 463.1811; found, 463.1811.


(ESI, m/z): [M+H]⁺ Calcd. For C₂₇H₂₇FN₂O₂S+H, 463.1856; found, 463.1850.

(Z)-N-(2-(4-(tert-Butyl)phenyl)-3-Fluoro-3-(1*H*-Indol-1-yl)allyl)-N,4-Dimethylbenzenesulfonamide (4q)



68.7 mg, 70% yield, Z/E = 18:1; eluent with petroleum ether/ethyl acetate = 10:1; colorless oil; ¹H NMR (400 MHz, CDCl₃) δ 7.62 (d, *J* = 8.0 Hz, 2H), 7.54 (d, *J* = 7.6 Hz, 1H), 7.28–7.32 (m, 3H), 7.12–7.21 (m, 4H), 6.95 (d, *J* = 8.0 Hz, 2H), 6.73 (d, *J* = 3.2 Hz, 1H), 6.43 (d, *J* = 3.2 Hz, 1H), 4.32 (s, 2H), 2.74 (s, 3H), 2.43 (s, 3H), 1.22 (s, 9H); ¹³C NMR (101 MHz, CDCl₃) δ 150.9, 147.6 (d, ¹J_{F-C} = 263.4 Hz), 143.6, 135.7 (d, ³J_{F-C} = 3.6 Hz), 134.0, 130.0 (d, ³J_{F-C} = 3.1 Hz), 129.8, 128.8, 127.7, 127.7, 127.5 (d, ³J_{F-C} = 3.1 Hz), 125.5, 123.4, 121.7, 121.1, 111.4 (d, ³J_{F-C} = 2.9 Hz), 109.0 (d, ²J_{F-C} = 23.7 Hz), 105.8 (d, ⁴J_{F-C} = 1.2 Hz), 48.1 (d, ³J_{F-C} = 2.9 Hz), 34.6, 34.1, 31.3, 21.6; ¹⁹F NMR (376 MHz, CDCl₃) δ -88.7 (s, 1F); IR (KBr): 3052, 2961, 1688, 1458, 1344, 746 cm⁻¹; HRMS (ESI, m/z): [M+H]⁺ Calcd. For C₂₉H₃₁FN₂O₂S+H, 491.2169; found, 491.2165.


(Z)-N-(3-Fluoro-3-(1*H*-Indol-1-yl)-2-(4-Methoxyphenyl)allyl)-N,4-Dimethylbenzenesulfonamide (4r)



57.6 mg, 62% yield, Z/E = 25:1; eluent with petroleum ether/ethyl acetate = 10:1; brown oil; ¹H NMR (400 MHz, CDCl₃) δ 7.67 (d, *J* = 8.4 Hz, 2H), 7.58 (d, *J* = 8.0 Hz, 1H), 7.33–7.36 (m, 3H), 7.17–7.26 (m, 2H), 6.98 (d, *J* = 8.8 Hz, 2H), 6.79 (d, *J* = 3.2 Hz, 1H), 6.69 (d, *J* = 8.8 Hz, 2H), 6.48 (d, *J* = 3.6 Hz, 1H), 4.34 (d, *J* = 2.8 Hz, 2H), 3.74 (s, 3H), 2.78 (s, 3H), 2.47 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 159.2, 147.2 (d, ¹J_{F-C} = 262.9 Hz), 143.6, 135.6 (d, ³J_{F-C} = 3.8 Hz), 134.1, 129.8, 129.4 (d, ³J_{F-C} = 3.2 Hz), 128.8, 127.7, 127.4 (d, ⁴J_{F-C} = 2.1 Hz), 125.3 (d, ³J_{F-C} = 3.2


Hz), 123.4, 121.7, 121.2, 114.1, 111.4 (d, $^3J_{F-C} = 2.8$ Hz), 109.0 (d, $^2J_{F-C} = 24.0$ Hz), 105.9 (d, $^4J_{F-C} = 1.3$ Hz), 55.2, 48.1 (d, $^3J_{F-C} = 2.7$ Hz), 34.2, 21.6; ^{19}F NMR (376 MHz, CDCl_3) δ -89.6 (s, 1F); IR (KBr): 3057, 2928, 1693, 1456, 1340, 743 cm^{-1} ; HRMS (ESI, m/z): $[\text{M}+\text{H}]^+$ Calcd. For $\text{C}_{26}\text{H}_{25}\text{FN}_2\text{O}_3\text{S}+\text{H}$, 465.1648; found, 465.1649.

(Z)-N-(3-Fluoro-2-(4-Fluorophenyl)-3-(1*H*-Indol-1-yl)allyl)-N,4-Dimethylbenzenesulfonamid e (4s)



56.2 mg, 62% yield, $Z/E = 21:1$; eluent with petroleum ether/ethyl acetate = 10:1; yellow oil; ^1H NMR (400 MHz, CDCl_3) δ 7.68 (d, $J = 8.4$ Hz, 2H), 7.58 (d, $J = 7.2$ Hz, 1H), 7.33–7.36 (m, 3H), 7.18–7.26 (m, 2H), 7.03–7.07 (m, 2H), 6.83–6.88 (m, 2H), 6.78 (d, $J = 3.6$ Hz, 1H), 6.50 (d, $J = 3.6$ Hz, 1H), 4.34 (d, $J = 2.8$ Hz, 2H), 2.79 (s, 3H), 2.47 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 162.3 (d, $^1J_{F-C} = 246.6$ Hz), 147.8 (d, $^1J_{F-C} = 263.4$ Hz), 143.8, 135.5 (d, $^3J_{F-C} = 3.7$ Hz), 134.0, 130.0 (d, $^3J_{F-C} = 3.1$ Hz), 129.9 (d, $^3J_{F-C} = 3.3$ Hz), 129.9, 128.8, 127.6, 127.1 (d, $^4J_{F-C} = 2.0$ Hz), 123.6, 121.9, 121.3, 115.7 (d, $^1J_{F-C} = 21.6$ Hz), 111.3 (d, $^3J_{F-C} = 2.8$ Hz), 108.6 (d, $^2J_{F-C} = 24.8$ Hz), 106.2 (d, $^4J_{F-C} = 1.2$ Hz), 48.4 (d, $^3J_{F-C} = 2.4$ Hz), 34.3, 21.6; ^{19}F NMR (376 MHz, $\text{DMSO}-d_6$) δ -87.0 (s, 1F), -114.0 – -113.6(m, 1F); IR (KBr): 3057, 2928, 1694, 1456, 1342, 745 cm^{-1} ; HRMS (ESI, m/z): $[\text{M}+\text{H}]^+$ Calcd. For $\text{C}_{25}\text{H}_{22}\text{F}_2\text{N}_2\text{O}_2\text{S}+\text{H}$, 453.1448; found, 453.1451.


(Z)-N-(2-(4-Chlorophenyl)-3-Fluoro-3-(1*H*-Indol-1-yl)allyl)-N,4-Dimethylbenzenesulfonamide (4t)



56.3 mg, 60% yield, $Z/E = 26:1$; eluent with petroleum ether/ethyl acetate = 10:1; yellow oil; ^1H NMR (400 MHz, CDCl_3) δ 7.67 (d, $J = 8.4$ Hz, 2H), 7.59 (d, $J = 7.6$ Hz, 1H), 7.35 (d, $J = 8.4$ Hz, 3H), 7.21–7.29 (m, 2H), 7.13 (d, $J = 8.4$ Hz, 2H), 7.00 (d, $J = 8.4$ Hz, 2H), 6.76 (d, $J = 3.6$ Hz,


1H), 6.50 (d, $J = 3.6$ Hz, 1H), 4.34 (d, $J = 2.8$ Hz, 2H), 2.79 (s, 3H), 2.48 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 147.9 (d, ${}^1J_{F-C} = 263.4$ Hz), 143.8, 135.5 (d, ${}^3J_{F-C} = 3.7$ Hz), 134.0, 133.9, 131.8 (d, ${}^3J_{F-C} = 3.4$ Hz), 129.8, 129.5 (d, ${}^3J_{F-C} = 3.1$ Hz), 128.9, 128.8, 127.6, 127.1 (d, ${}^4J_{F-C} = 1.9$ Hz), 123.6, 122.0, 121.3, 111.3 (d, ${}^3J_{F-C} = 2.9$ Hz), 108.4 (d, ${}^2J_{F-C} = 24.9$ Hz), 106.3 (d, ${}^4J_{F-C} = 1.2$ Hz), 48.2 (d, ${}^3J_{F-C} = 2.6$ Hz), 34.2, 21.6; ^{19}F NMR (376 MHz, CDCl_3) δ -87.6 (s, 1F); IR (KBr): 3056, 2928, 1692, 1455, 1342, 746 cm^{-1} ; HRMS (ESI, m/z): [M+H]⁺ Calcd. For $\text{C}_{25}\text{H}_{22}\text{ClFN}_2\text{O}_2\text{S}+\text{H}$, 469.1153; found, 469.1151.

(Z)-N-(3-Fluoro-3-(1*H*-Indol-1-yl)-2-(Trifluoromethyl)phenylallyl)-N,4-Dimethylbenzenesulfonamide (4u)



61.3 mg, 61% yield, $Z/E > 30:1$; eluent with petroleum ether/ethyl acetate = 10:1; yellow oil; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 7.69 (d, $J = 8.0$ Hz, 2H), 7.53 (d, $J = 8.4$ Hz, 3H), 7.45 (d, $J = 8.0$ Hz, 2H), 7.33–7.38 (m, 3H), 7.28 (d, $J = 3.2$ Hz, 1H), 7.18 (t, $J = 7.6$ Hz, 1H), 7.12 (t, $J = 7.6$ Hz, 1H), 6.59 (d, $J = 3.2$ Hz, 1H), 4.32 (s, 2H), 2.71 (s, 3H), 2.41 (s, 3H); ^{13}C NMR (101 MHz, $\text{DMSO}-d_6$) δ 147.4 (d, ${}^1J_{F-C} = 266.5$ Hz), 144.1, 138.3 (d, ${}^4J_{F-C} = 2.1$ Hz), 135.6 (d, ${}^3J_{F-C} = 3.7$ Hz), 133.7, 130.4, 129.4 (d, ${}^3J_{F-C} = 2.8$ Hz), 128.7, 128.6 (d, ${}^3J_{F-C} = 2.6$ Hz), 128.5 (q, ${}^2J_{F-C} = 31.6$ Hz), 127.8, 125.5 (d, ${}^3J_{F-C} = 3.7$ Hz), 124.4 (q, ${}^2J_{F-C} = 270.6$ Hz), 123.7, 122.1, 121.5, 111.3, 111.1 (d, ${}^2J_{F-C} = 24.9$ Hz), 106.4, 48.9 (d, ${}^3J_{F-C} = 2.6$ Hz), 35.0, 21.4; ^{19}F NMR (376 MHz, $\text{DMSO}-d_6$) δ -61.2 (s, 3F), -85.5 (s, 1F); IR (KBr): 3059, 2928, 1690, 1456, 1330, 746 cm^{-1} ; HRMS (ESI, m/z): [M+H]⁺ Calcd. For $\text{C}_{26}\text{H}_{22}\text{F}_4\text{N}_2\text{O}_2\text{S}+\text{H}$, 503.1416; found, 503.1413.


(Z)-N-(3-Fluoro-3-(1*H*-Indol-1-yl)-2-(Naphthalen-2-ylallyl)-N,4-Dimethylbenzenesulfonamide (4v)



58.2 mg, 60% yield, $Z/E = 17:1$; eluent with petroleum ether/ethyl acetate = 10:1; brown solid, mp: 141–142 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.73 (d, $J = 7.2$ Hz, 1H), 7.68 (s, 2H), 7.62 (d, $J = 7.6$ Hz, 2H), 7.58 (d, $J = 8.0$ Hz, 2H), 7.46 (d, $J = 4.8$ Hz, 3H), 7.27 (d, $J = 8.0$ Hz, 1H), 7.18–7.25 (m, 3H), 6.99 (d, $J = 8.4$ Hz, 1H), 6.76 (d, $J = 2.8$ Hz, 1H), 6.42 (d, $J = 2.4$ Hz, 1H), 4.50 (s, 2H), 2.85 (s, 3H), 2.41 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 148.2 (d, $^1J_{F-C} = 264.0$ Hz), 143.5, 135.6 (d, $^3J_{F-C} = 3.7$ Hz), 134.2, 133.3, 132.7, 130.8 (d, $^3J_{F-C} = 3.3$ Hz), 129.7, 128.9, 128.3, 127.6 (d, $^3J_{F-C} = 3.9$ Hz), 127.6, 127.5, 126.4, 126.3, 125.7 (d, $^4J_{F-C} = 2.2$ Hz), 123.5, 121.8, 121.2, 111.5 (d, $^3J_{F-C} = 3.3$ Hz), 109.0 (d, $^2J_{F-C} = 24.0$ Hz), 106.1 (d, $^4J_{F-C} = 1.2$ Hz), 48.4 (d, $^4J_{F-C} = 2.5$ Hz), 34.2, 21.6; ^{19}F NMR (376 MHz, CDCl_3) δ -88.3 (s, 1F); IR (KBr): 3055, 2925, 1689, 1456, 1340, 744 cm^{-1} ; HRMS (ESI, m/z): [M+H]⁺ Calcd. For $\text{C}_{29}\text{H}_{25}\text{FN}_2\text{O}_2\text{S}+\text{H}$, 485.1699; found, 485.1693.


(Z)-N-(2-(Benzo[d][1,3]dioxol-5-yl)-3-Fluoro-3-(1H-Indol-1-yl)allyl)-N,4-

Dimethylbenzenesulfonamide (4w)



59.3 mg, 62% yield $Z/E = 12:1$; eluent with petroleum ether/ethyl acetate = 6:1; brown oil; ^1H NMR (500 MHz, CDCl_3) δ 7.64 (d, $J = 8.0$ Hz, 2H), 7.54 (d, $J = 7.5$ Hz, 1H), 7.29–7.32 (m, 3H), 7.20 (t, $J = 7.0$ Hz, 1H), 7.15 (t, $J = 7.0$ Hz, 1H), 6.77 (d, $J = 3.0$ Hz, 1H), 6.56 (d, $J = 8.0$ Hz, 1H), 6.53 (d, $J = 8.0$ Hz, 1H), 6.43–6.46 (m, 2H), 5.83 (s, 2H), 4.25 (s, 2H), 2.75 (s, 3H), 2.42 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 147.8, 147.5 (d, $^1J_{F-C} = 265.4$ Hz), 147.3, 143.7, 135.6 (d, $^3J_{F-C} = 3.6$ Hz), 134.1, 129.8, 128.8, 127.6, 127.3 (d, $^4J_{F-C} = 2.5$ Hz), 126.9 (d, $^3J_{F-C} = 3.2$ Hz), 123.5, 122.1 (d, $^3J_{F-C} = 3.4$ Hz), 121.7, 121.2, 111.3 (d, $^3J_{F-C} = 3.0$ Hz), 109.0 (d, $^2J_{F-C} = 24.7$ Hz), 108.5, 108.5 (d, $^3J_{F-C} = 3.3$ Hz), 106.0, 101.2, 48.5 (d, $^4J_{F-C} = 2.6$ Hz), 34.2, 21.6; ^{19}F NMR (471 MHz, CDCl_3) δ -89.2 (s, 1F); IR (KBr): 3059, 2900, 1693, 1451, 1340, 746 cm^{-1} ; HRMS (ESI, m/z): [M+H]⁺ Calcd. For $\text{C}_{26}\text{H}_{23}\text{FN}_2\text{O}_4\text{S}+\text{H}$, 479.1441; found, 479.1446.


(Z)-N-(3-Fluoro-3-(1H-Indol-1-yl)-2-(Quinolin-3-yl)allyl)-N,4-Dimethylbenzenesulfonamide (4x)



56.3 mg, 58% yield, $Z/E > 30:1$; eluent with petroleum ether/ethyl acetate = 6:1; yellow solid, mp: 143–144 °C; ^1H NMR (400 MHz, DMSO- d_6) δ 8.42 (s, 1H), 8.23 (s, 1H), 7.87 (d, $J = 8.4$ Hz, 1H), 7.78 (d, $J = 8.0$ Hz, 1H), 7.67–7.72 (m, 3H), 7.56 (d, $J = 8.0$ Hz, 1H), 7.52 (d, $J = 7.6$ Hz, 1H), 7.38–7.43 (m, 4H), 7.15 (t, $J = 7.6$ Hz, 1H), 7.08 (t, $J = 7.6$ Hz, 1H), 6.58 (d, $J = 2.8$ Hz, 1H), 4.43 (s, 2H), 2.77 (s, 3H), 2.37 (s, 3H); ^{13}C NMR (101 MHz, DMSO- d_6) δ 150.2, 147.5 (d, $^1J_{F-C} = 267.6$ Hz), 146.9, 144.1, 135.6 (d, $^3J_{F-C} = 3.9$ Hz), 135.6 (d, $^3J_{F-C} = 3.8$ Hz), 133.9, 130.4, 129.0, 128.7 (d, $^3J_{F-C} = 2.9$ Hz), 128.6, 128.5, 127.7, 127.4, 127.3 (d, $^3J_{F-C} = 3.7$ Hz), 123.8, 122.1, 121.5, 111.3, 109.7 (d, $^2J_{F-C} = 27.4$ Hz), 106.5, 48.9, 35.2, 21.5; ^{19}F NMR (376 MHz, DMSO- d_6) δ -85.2 (s, 1F); IR (KBr): 3052, 2937, 1692, 1460, 1328, 741 cm $^{-1}$; HRMS (ESI, m/z): [M+H] $^+$ Calcd. For C₂₈H₂₄FN₃O₂S+H, 486.1652; found, 486.1660.

E. Late-stage Functionalization of Drug Molecules


The Synthesis of 9a



$t\text{-BuOLi}$ (5 equiv) was added to the solution of *N*-methylsulfonamide **8a** (0.2 mmol), (trifluoromethyl)alkene **2a** (4 equiv) and DMF (4 mL). Then *N*-methylmethanesulfonamide **3c** (5 equiv) was added by portions to the mixture within 20 minutes. The reaction mixture was vigorously stirred at room temperature for 3 h. Then the mixture was stopped stirring, added water (15 mL), extracted with EtOAc (15 mL \times 3). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. Further purification by flash column chromatography on silica gel (eluting with petroleum ether/ethyl acetate = 3:1) provided the


product **9a** in 70% isolated yield.

(Z)-N-(1-Fluoro-3-(*N*-Methylmethysulfonamido)-2-Phenylprop-1-en-1-yl)-*N*-Methyl-4-(*p*-Tolyl)-3-(Trifluoromethyl)-1*H*-Pyrazol-1-yl)benzenesulfonamide (9a**)**



89.1 mg, 70% yield, *Z/E* > 30:1; eluent with petroleum ether/ethyl acetate = 3:1; white solid; ¹H NMR (500 MHz, CDCl₃) δ 7.70 (d, *J* = 8.5 Hz, 2H), 7.37–7.45 (m, 6H), 7.34 (d, *J* = 7.0 Hz, 1H), 7.19 (d, *J* = 8.0 Hz, 2H), 7.11 (d, *J* = 8.0 Hz, 2H), 6.75 (s, 1H), 4.31 (d, *J* = 2.0 Hz, 2H), 2.84 (s, 3H), 2.77 (s, 3H), 2.39 (s, 3H), 2.38 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 149.1 (d, ¹J_{F-C} = 279.4 Hz), 145.4, 144.6 (q, ²J_{F-C} = 30.8 Hz), 143.2, 140.0, 137.2, 133.7 (d, ³J_{F-C} = 3.2 Hz), 129.9, 129.1 (d, ⁴J_{F-C} = 1.3 Hz), 129.0, 128.8, 128.7 (d, ⁴J_{F-C} = 1.2 Hz), 128.7, 125.8, 125.5, 120.9 (q, ¹J_{F-C} = 265.9 Hz), 116.6 (d, *J* = 27.7 Hz), 106.6, 48.6 (d, ³J_{F-C} = 1.8 Hz), 37.0, 36.2, 33.8, 21.4; ¹⁹F NMR (471 MHz, CDCl₃) δ -62.5 (d, *J* = 3.8 Hz, 3F), -91.8 (s, 1F); IR (KBr): 3054, 2939, 1704, 1474, 1118 cm⁻¹; HRMS (APCI, m/z): [M+H]⁺ Calcd. For C₂₉H₂₈F₄N₄O₄S₂+H, 637.1561; found, 637.1552.


The Synthesis of **9b**



t-BuOLi (5 equiv) was added to the solution of *N*-methylsulfonamide **8b** (0.2 mmol), (trifluoromethyl)alkene **2a** (4 equiv) and DMF (4 mL). Then *N*-methylmethanesulfonamide **3c** (5 equiv.) was added by portions to the mixture within 20 minutes. The reaction mixture was vigorously stirred at room temperature for 3 h. Then the mixture was stopped stirring, added water (15 mL), extracted with EtOAc (15 mL × 3). The combined organic phases were dried over anhydrous Na₂SO₄, filtered and concentrated *in vacuo*. Further purification by flash column chromatography on silica gel (eluting with petroleum ether/ethyl acetate = 2:1) provided the

product **9b** in 75% isolated yield.


(Z)-4-(1,1-Dioxido-1,2-Thiazinan-2-yl)-N-(1-Fluoro-3-(N-Methylmethylsulfonamido)-2-Phenylprop-1-en-1-yl)-N-Methylbenzenesulfonamide (9b)



81.8 mg, 75% yield, *Z/E* = 6:1; eluent with petroleum ether/ethyl acetate = 2:1; colorless oil; ¹H NMR (400 MHz, CDCl₃) δ 7.60–7.70 (m, 2H), 7.34–7.42 (m, 7H), 4.33 (s, 2H), 3.81 (s, 2H), 3.22 (s, 2H), 2.85 (d, *J* = 2.8 Hz, 3H), 2.78 (s, 3H), 2.39 (s, 3H), 2.32–2.37 (m, 2H), 1.93 (d, *J* = 3.6 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 149.3 (d, ¹J_{F-C} = 279.7 Hz), 145.2, 135.6, 133.7 (d, ³J_{F-C} = 2.7 Hz), 128.9, 128.9, 128.7, 128.7, 126.3, 116.2 (d, ²J_{F-C} = 28.0 Hz), 53.0, 51.0, 48.6 (d, ³J_{F-C} = 2.1 Hz), 36.9, 36.2, 33.7, 24.4, 24.2; ¹⁹F NMR (376 MHz, CDCl₃) δ -90.9 (s, 1F); IR (KBr): 3043, 2931, 1475, 1369, 1158 cm⁻¹; HRMS (APCI, m/z): [M+H]⁺ Calcd. For C₂₂H₂₈FN₃O₆S₃+H, 546.1197; found, 546.1186.


F. X-ray Crystallographic Data

The X-ray crystallographic structures for **4a**. ORTEP representation with 50% probability thermal ellipsoids. Solvent and hydrogen are omitted for clarity. Crystal data have been deposited to CCDC, number 2036948.



Empirical formula	C ₂₅ H ₂₄ FN ₂ O ₂ S
Formula weight	434.51
Temperature	170 K
Crystal system, Space group	Triclinic, P -1
Unit cell dimensions	a = 10.5052(14) Å alpha = 96.383(5) deg. b = 10.7663(14) Å beta = 108.432(5) deg. c = 11.1339(15) Å gamma = 110.430(4) deg.
Volume	1084.2(3) Å ³
Z	2
ρ _{calcd} /cm ³	1.331
μ/mm 1	0.183 mm ¹
F(000)	456.0
Crystal size	0.16 × 0.11 × 0.08 mm ³
Radiation	MoKα (λ = 0.71073)
Theta range for data collection	2.237 to 26.329 deg.
Index ranges	-13 ≤ h ≤ 13, -13 ≤ k ≤ 12, -13 ≤ l ≤ 13
Reflections collected	12498
Independent reflections	3563 [R _{int} = 0.0309, R _{sigma} = 0.0360]
Data/restraints/parameters	3563/0/282
Goodness-of-fit on F ²	1.030
Final R indexes [I>=2σ (I)]	R ₁ = 0.0416, wR ₂ = 0.0952
Final R indexes [all data]	R ₁ = 0.0563, wR ₂ = 0.1042

The X-ray crystallographic structures for **4n**. ORTEP representation with 50% probability thermal ellipsoids. Solvent and hydrogen are omitted for clarity. Crystal data have been deposited to CCDC, number 2036972.




Empirical formula	C ₁₈ H ₂₀ FN ₃ O ₆ S ₂
Formula weight	457.49
Temperature	170 K
Crystal system, Space group	Monoclinic, P 1 21/n 1
Unit cell dimensions	a = 6.3919(6) Å alpha = 90 deg. b = 13.7713(13) Å beta = 94.388(3) deg. c = 23.551(2) Å gamma = 90 deg.
Volume	2067.0(3) Å ³
Z	4
ρ _{calc} g/cm ³	1.470
μ/mm ⁻¹	0.307 mm ⁻¹
F(000)	952
Crystal size	0.19 × 0.12 × 0.05 mm ³
Radiation	MoK\alpha (λ = 0.71073)
Theta range for data collection	2.994 to 26.123 deg.
Index ranges	-7 ≤ h ≤ 7, -17 ≤ k ≤ 17, -29 ≤ l ≤ 28
Reflections collected	22873
Independent reflections	4207 [R _{int} = 0.0687, R _{sigma} = 0.0526]
Data/restraints/parameters	4207/0/274
Goodness-of-fit on F ²	1.056

Final R indexes [$I \geq 2\sigma(I)$]	$R_1 = 0.0757$, $wR_2 = 0.2276$
---	----------------------------------


Final R indexes [all data]	$R_1 = 0.1071$, $wR_2 = 0.2505$
----------------------------	----------------------------------

G. NMR Spectra of New Compounds


¹H NMR (400 MHz, CDCl₃) spectrum for 4a




¹³C NMR (101 MHz, CDCl₃) spectrum for 4a




¹⁹F NMR (376 MHz, CDCl₃) spectrum for 4a




¹H NMR (400 MHz, DMSO-d₆) spectrum for 4b




¹³C NMR (101 MHz, DMSO-*d*₆) spectrum for 4b




¹⁹F NMR (376 MHz, DMSO-*d*₆) spectrum for 4b




¹H NMR (500 MHz, CDCl₃) spectrum for 4c




¹³C NMR (126 MHz, CDCl₃) spectrum for 4c




¹⁹F NMR (471 MHz, CDCl₃) spectrum for 4c




¹H NMR (400 MHz, CDCl₃) spectrum for 4d




¹³C NMR (101 MHz, CDCl₃) spectrum for 4d




¹⁹F NMR (376 MHz, CDCl₃) spectrum for 4d




¹H NMR (400 MHz, DMSO-*d*₆) spectrum for 4e




¹³C NMR (101 MHz, DMSO-*d*₆) spectrum for 4e




¹⁹F NMR (376 MHz, DMSO-*d*₆) spectrum for 4e




¹H NMR (400 MHz, DMSO-*d*₆) spectrum for 4f




¹³C NMR (101 MHz, DMSO-*d*₆) spectrum for 4f




¹⁹F NMR (376 MHz, DMSO-*d*₆) spectrum for 4f




¹H NMR (400 MHz, DMSO-*d*₆) spectrum for 4g




¹³C NMR (101 MHz, DMSO-*d*₆) spectrum for 4g




¹⁹F NMR (376 MHz, DMSO-*d*₆) spectrum for 4g




¹H NMR (400 MHz, DMSO-*d*₆) spectrum for 4h




¹³C NMR (101 MHz, DMSO-*d*₆) spectrum for 4h




¹⁹F NMR (376 MHz, DMSO-*d*₆) spectrum for 4h




¹H NMR (500 MHz, DMSO-*d*₆) spectrum for 4i




¹³C NMR (126 MHz, DMSO-*d*₆) spectrum for 4i




¹⁹F NMR (471MHz, DMSO-*d*₆) spectrum for 4i




¹H NMR (400 MHz, CDCl₃) spectrum for 4j




¹³C NMR (101 MHz, CDCl₃) spectrum for 4j




¹⁹F NMR (376 MHz, CDCl₃) spectrum for 4j




¹H NMR (400 MHz, CDCl₃) spectrum for 4k




¹³C NMR (101 MHz, CDCl₃) spectrum for 4k




¹⁹F NMR (376 MHz, CDCl₃) spectrum for 4k




¹H NMR (400 MHz, CDCl₃) spectrum for 4l




¹³C NMR (100 MHz, CDCl₃) spectrum for 4l




¹⁹F NMR (376 MHz, CDCl₃) spectrum for 4l




¹H NMR (400 MHz, CDCl₃) spectrum for 4m




¹³C NMR (101 MHz, CDCl₃) spectrum for 4m




¹⁹F NMR (376 MHz, CDCl₃) spectrum for 4m




¹H NMR (400 MHz, CDCl₃) spectrum for 4n




¹³C NMR (101 MHz, CDCl₃) spectrum for 4n




¹⁹F NMR (471 MHz, CDCl₃) spectrum for 4n




¹H NMR (400 MHz, CDCl₃) spectrum for 4o




¹³C NMR (101 MHz, CDCl₃) spectrum for 4o




¹⁹F NMR (376 MHz, CDCl₃) spectrum for 4o




¹H NMR (400 MHz, CDCl₃) spectrum for 4p




¹³C NMR (101 MHz, CDCl₃) spectrum for 4p




¹⁹F NMR (376 MHz, CDCl₃) spectrum for 4p




¹H NMR (400 MHz, CDCl₃) spectrum for 4q




¹³C NMR (101 MHz, CDCl₃) spectrum for 4q




¹⁹F NMR (376 MHz, CDCl₃) spectrum for 4q




¹H NMR (400 MHz, CDCl₃) spectrum for 4r




¹³C NMR (101 MHz, CDCl₃) spectrum for 4r




¹⁹F NMR (376 MHz, CDCl₃) spectrum for 4r




¹H NMR (400 MHz, CDCl₃) spectrum for 4s




¹³C NMR (101 MHz, CDCl₃) spectrum for 4s




¹⁹F NMR (376 MHz, CDCl₃) spectrum for 4s




¹H NMR (400 MHz, CDCl₃) spectrum for 4t




¹³C NMR (101 MHz, CDCl₃) spectrum for 4t




¹⁹F NMR (376 MHz, CDCl₃) spectrum for 4t




¹H NMR (400 MHz, DMSO-*d*₆) spectrum for 4u




¹³C NMR (101 MHz, DMSO-*d*₆) spectrum for 4u




¹⁹F NMR (376 MHz, DMSO-*d*₆) spectrum for 4u




¹H NMR (400 MHz, CDCl₃) spectrum for 4v




¹³C NMR (101 MHz, CDCl₃) spectrum for 4v




¹⁹F NMR (376 MHz, CDCl₃) spectrum for 4v




¹H NMR (500 MHz, CDCl₃) spectrum for 4w




¹³C NMR (126 MHz, CDCl₃) spectrum for 4w




¹⁹F NMR (471 MHz, CDCl₃) spectrum for 4w




¹H NMR (400 MHz, DMSO-d₆) spectrum for 4x




¹³C NMR (101 MHz, DMSO-*d*₆) spectrum for 4x




¹⁹F NMR (376 MHz, DMSO-*d*₆) spectrum for 4x




¹H NMR (500 MHz, CDCl₃) spectrum for 9a




¹³C NMR (126 MHz, CDCl₃) spectrum for 9a




¹⁹F NMR (471 MHz, CDCl₃) spectrum for 9a



¹H NMR (400 MHz, CDCl₃) spectrum for 9b



¹³C NMR (101 MHz, CDCl₃) spectrum for 9b



¹⁹F NMR (376 MHz, CDCl₃) spectrum for 9b

